US 9566278
Protein kinase C inhibitors and uses thereof
granted A61KA61K31/506A61P
Quick answer
US patent 9566278 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/506, A61P, A61P27/02, A61P29/00